PneumocystisC_PAPYNCT07004127
Pneumocystis in Patients Over 75 Year
An observational study of Pneumocystis, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV. Read more about this study
- Who is it for?
- Ages 75 years and older
- Conditions the study is for
- Pneumocystis
- How many people
- 162 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2010to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: geriatric patient with pneumocystis, not HIV positive, over 75 years old
Who may be able to join
- Patient > or equal to 75 years of age
- Microbiological diagnosis:
- Direct examination with standard stain, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum) And/or
- Direct examination with immunofluorescence, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum)
- And/or
- Positive PCR (BAL, sputum, nasopharyngeal swab or blood) and CT < 35
Show all 10Show fewer
- Absence of HIV infection
- Hospitalization in French hospitals between 2010 and 2021
- Non-inclusion criteria
- 1. Opposition of the patient to participate to the study
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Pneumocystis in Non-HIV Patients Over 75 Years Old: Epidemiological, Diagnostic, Microbiological and Therapeutic Characteristics
Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV.
Worldwide, the profile of patients affected by this pathology is changing due to two main factors:
Read more
- The sustainable stabilization of HIV patients.
- The emergence of new risk factors of immunosuppression. The geriatric population is particularly affected by these risk factors, increasing the incidence of pneumocystis in this population, which does not have HIV (solid cancer, hemopathy, immunosuppressive treatments, etc.).
There is currently no work specifically studying pneumocystis in this age group. The main objective of this study is to describe the clinical, biological and therapeutic data of a cohort of geriatric patients with pneumocystis, not carrying HIV, from January 1, 2010 to December 31, 2021, in all the centers surveyed.
- Conditions
- Pneumocystis
- Medical subject headings
- Pneumonia, Pneumocystis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| geriatric patient with pneumocystis | geriatric patient with pneumocystis, not HIV positive, |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical data
description of clinical data
Measured: From DAY 0 to end of treatment
Therapeutic data
description of treatment provide to treat pneumocystosis
Measured: From DAY 0 to end of treatment
Biological data
Analysis of biological data realized during follow up
Measured: From DAY 0 to end of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2025
- Study start1 Jan 2010
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumocystisStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 162 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Adrien BARRAUD, Principal investigator, CHU NIMESAlbert SOTTO, Md, PhD, Study director, CHU NIMES
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07004127
- Sponsor's protocol ID
- IRB_22.01.05
- Acronym
- C_PAPY
- Status last verified
- Apr 2023
- First submitted
- 31 Aug 2022
- Last updated
- 4 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pneumocystis in Non-HIV Patients Over 75 Years Old: Epidemiological, Diagnostic, Microbiological and Therapeutic Characteristics
- ClinicalTrials.gov ID
- NCT07004127
- Acronym / sponsor ID
- C_PAPY / IRB_22.01.05
- Conditions
- Pneumocystis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 162 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 1 Jan 2010 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 4 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV.
Worldwide, the profile of patients affected by this pathology is changing due to two main factors:
- The sustainable stabilization of HIV patients.
- The emergence of new risk factors of immunosuppression. The geriatric population is particularly affected by these risk factors, increasing the incidence of pneumocystis in this population, which does not have HIV (solid cancer, hemopathy, immunosuppressive treatments, etc.).
There is currently no work specifically studying pneumocystis in this age group. The main objective of this study is to describe the clinical, biological and therapeutic data of a cohort of geriatric patients with pneumocystis, not carrying HIV, from January 1, 2010 to December 31, 2021, in all the centers surveyed.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| geriatric patient with pneumocystis | – | –geriatric patient with pneumocystis, not HIV positive, |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- geriatric patient with pneumocystis, not HIV positive, over 75 years old
Key inclusion criteria (10 listed)
- Patient > or equal to 75 years of age
- Microbiological diagnosis:
- Absence of HIV infection
- Hospitalization in French hospitals between 2010 and 2021
- Non-inclusion criteria
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Clinical data
Time frame: From DAY 0 to end of treatment
description of clinical data
Therapeutic data
Time frame: From DAY 0 to end of treatment
description of treatment provide to treat pneumocystosis
Biological data
Time frame: From DAY 0 to end of treatment
Analysis of biological data realized during follow up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Pneumocystis
Not yet recruitingPhase 3
Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia
Pneumocystis Jirovecii Pneumonia
RecruitingPhase 1/2
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection
Active, not recruiting
Improving PCP Advance Care Planning for People With ADRD
Alzheimer Disease, Dementia
Not yet recruiting
Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP
Familial Hypercholesterolemia
Not yet recruitingPhase 2/3
Intra Articular Injection of Peripheral Blood Mononuclear Cells for Knee Osteoarthritis
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adrien BARRAUD principal investigator
CHU NIMES
Albert SOTTO, Md, PhD study director
CHU NIMES
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumocystis, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical data (time frame: From DAY 0 to end of treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2025.